A subset of ER+ tumors showed an overexpression of RET and GFRα1[61-63], which correlates with decreased metastasis-free survival[64,65], thus confirming the importance of RET in the development of ER+ cancers and making it a promising target to avoid tamoxifen resistance and improve effects of hormone therapy in BC[60]. Here, ESR1 is linked to breast cancer.